Prevention and treatment of chemotherapy-induced digestive toxicities;Prévenir et traiter les complications digestives de la chimiothérapie anticancéreuse

Bulletin du Cancer

Volumn 88, Issue 2, 2001, Pages 163-173

  Boige, V ^a   Ducreux, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Diarrhea; Mucositis; Nausea; Prevention; Toxicity; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; MUCOSA INFLAMMATION; NAUSEA; QUALITY OF LIFE; REVIEW; TUMOR CELL;

ANTINEOPLASTIC AGENTS; DIARRHEA; DRUG THERAPY, COMBINATION; ENTEROCOLITIS; HUMANS; NAUSEA; NEUTROPENIA; VOMITING;

EID: 0035068360     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
2. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: A multicenter, double blind, randomized, parallel group study
3. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis
4. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
5. A comparison of oral ondansetron syrup and intravenous ondansetron regimens given in combination with oral dexamethasone for the prevention of emesis and nausea in paediatric patients receiving moderately/highly emetogenic chemotherapy
6. Double-blind randomized comparison of oral ondansetron and iv ondansetron for regimen-related nausea and vomiting in patients undergoing stem cell transplants
7. Costs of treating and preventing nausea and vomiting patients receiving chemotherapy
8. Optimal dose of intravenous dexamethazone in the prevention of cisplatine-induced acute emesis: A double-blind randomized trial
9. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
10. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
11. Controlling delayed vomiting: Double-blind, randomized trial, comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
12. Ondansetron vs metoclopramide both combined with dexamethasone in the prevention of cisplarin-induced delayed emesis
13. Dexamethasone with oral granisetron or metoclopramide in preventing chemotherapy-induced delayed emesis
14. Efficacy of a single 1 mg or 2 mg dose of oral granisetron for the prevention of nausea and vomiting induced by iv cyclophosphamide or carboplatin-based chemotherapy regimens
15. Use of an NK-1 receptor antagonist to prevent delayed emesis following cisplatin
16. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
17. Comparison of a neurokinin-1 antagonist, L-758.298, to ondansetron in the prevention of cisplatin-induced emesis
18. Reduction of cisplatin-induced emesis by selective neurokinin-I antagonist
19. Prevention of cisplatin-induced emesis by the selective neurokinin-1 antagonist, L-754.030, and its prodrug L-758.298
20. Cisapride and dexamethasone in the prevention of cisplatin-induced delayed emesis
21. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil
22. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
23. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy
24. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease
25. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma
26. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin
27. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
28. Effect of topical oral G-CSF on oral mucositis: A randomised placebo-controlled trial
29. Interleukine 1 increases thymidine labelling index of normal tissue of mice but not the tumor
30. The biological basis for the attenuation of mucositis: The example of interleukin-11
31. Insulin-like growth facror-I (IGF-I) stimulates regrowth of the damaged intestine in rats, when administered following, but not concurrent with, methotrexate
32. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β-3
33. Phase I study of transforming growth factor-beta3 mouthwasches for prevention of Chemotherapy-induced mucositis
34. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy
35. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy
36. Clinical evaluation of MGI 209, an anesthetic film-forming agent for relief from painful oral ulcers associated With chemotherapy
37. Oral capsain provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy
38. Vitamin E in the treatment of chemotherapy-induced mucositis
39. Laser effects on oral mucositis in patients receiving chemotherapy
40. Effect of granulocyte macrophage stimulating factor (GM-CSF) mouth-wash on grade III chemotherapy-induced oral mucositis
41. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma
42. Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study
43. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus highdose leucovorin
44. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer
45. Bowel rest, intravenous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma
46. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial
47. Octreotide acetate in the treatment of fluotouracil-induced diarrhea
48. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients
49. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer
50. CPT-11 in 5-FU resistant colorectal cancer: Management of delayed diarrhea
51. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
52. High-dose acetorphan (HDA) versus acetorphan + loperamide in the treatment of CPT-11 induced diarrhea: Preliminary report of a randomized phase II study in patients with advanced colorectal cancer
53. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-FU induced diarrhea and failure of loperamide treatment
54. Weekly irinotecan, leucovorin, and fluorouracil is superior to daily x 5 LV/FU in patients with previously untreated metastatic colorectal cancer
55. A randomized phase III trial comparing irinotecan + 5-FU/folinic acid to the same schedule of 5-FU/FA in patients with metastatic colorectal cancer as front line chemotherapy
56. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat
57. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002
58. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
59. Final results of a phase I and pharmacokinetic study of DX-8951f in patients with advanced tumors
60. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
61. Les entérocolites neutropéniques: Probèmes diagnostiques et thérapiques
62. Neutropenic enterocolitis: Spectrum of the disease and comparison of definite and possible cases
63. Changing presentation an management of neutropenic enterocolitis
64. Adynamic ileus in a patient with nonsmall-cell lung cancer after treatment with vinorelbine
65. Prostaglandin F2 alpha in the treatment of vinca alkaloid-induced ileus
66. Anal pruritus after cancer chemotherapy with gerhcitabine
67. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma: Result of a chronopharmacologic phase I trial
68. Chronomodulared versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: A multiinstitutional trial
69. Randomized multicentre trial of chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and leucovorin in metastatic colorectal cancer
70. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
71. Amifostine pre-treatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer
72. Glutathione reduces the toxicity and improves the quality of life of women diagnosed with ovarian cancer treated by cisplatin: Results of a double-blind randomised trial
73. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma
74. A randomized trial comparing the toxicity of high-dose chemotherapy with carboplatin, etoposide and ifosfamide plus PBSC transplantation (HD-VIC) with or without amifostine in patients with solid tumors
75. Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice
76. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines